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micro rnas (mirna) are an abundant class of small rnas that regulate the stability and translation of 
cognate mrnas. mirnas are potential diagnostic markers, moreover, they play an essential role in the 
development of various heart disesases. in case of limited tissue material, such as e.g. human biopsies, 
purification of miRNAs with sufficient yield is critical. Reproducible expression analysis of miRNAs is 
highly dependent on the quality of the RNA, which is often difficult to achieve from fibrous tissue such 
as the heart. Several companies developed general purification kits for miRNAs, however, none of them 
are specialized to fibrotic tissues. Here we describe an optimized miRNA purification protocol that results 
in high mirna yield as compared to other methods including trizol-based and column-based protocols. 
By using our improved protocol, mirna obtained from heart tissue gave more reproducible results in 
QRT-PCR analysis and obtained more significant calls (172 vs. 118) during DNA microarray analysis 
when compared to the commercially available kit. In addition to the heart tissue, the present protocol can 
be applied to other fibrotic tissues, such as lung or skeletal muscle to isolate high-purity miRNA. 
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introDuction
mirnas are small, noncoding rnas typically act as negative regulators of the 
expression of protein-encoding genes [1, 2]. Mature miRNAs target and bind to tran-
scripts and interfere with their translation into protein. They cause either transla-
tional repression or mrna degradation, depending on their degrees of complemen-
tarity or homology with target genes [17]. Generally, miRNAs are believed to cause 
translational repression due to partial pairing between miRNA and target mRNA.
several reports have indicated that mirnas play critical roles in essential bio-
logic processes [16, 19, 21]. Each miRNA has a special capability to potentially 
regulate the expression of dozens of protein coding genes and thereby modulate sev-
eral cellular pathways including those involved in differentiation, proliferation, apop-
tosis, and stress response [21]. Besides changes in the mRNA levels, down- or up-
regulation of miRNA expression in tissues have been correlated with several clini-
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cally important diseases, for example cancer as well as cardiovascular, metabolic, and 
neurologic diseases [3, 8, 11, 20].
The first evidence of a potential role for miRNAs in cardiovascular diseases was 
the observation by van Roojid et al. in 2006 [18] showing that overexpression of 
stress-inducible miRNAs was sufficient to induce hypertrophy in cultured cardio-
myocytes. since then, several research groups have reported that mirnas play an 
essential role in the development of cardiovascular diseases [9, 12, 13]. Accumulating 
evidence suggests that circulating mirnas are promising stable biomarkers for diag-
nosis of different types of cancer and cardiovascular diseases [6, 7].
The storage and purification of miRNAs from samples are crucial for miRNA 
expression analysis. Because of the low molecular weight and low abundance of 
miRNA, their enrichment is an important step for the measurement of expression [15, 
22]. By using total RNA to profile miRNA expression instead of purified miRNA can 
limit sensitivity because of the relative abundance of small rnas in a total rna 
sample [14]. Traditionally, miRNA purification relies on organic extraction followed 
by alcohol precipitation, however, much of the small RNAs are lost during this pro-
cedure. Several companies developed special purification kits for miRNAs that 
employ organic extraction followed by binding and purification of small RNAs on a 
silica fiber matrix. However, none of the commercially available kits are specialized 
to fibrotic tissues, such as the myocardial tissue. In case of limited quantity of tissue 
samples, e.g. human heart or lung biopsies, purification of miRNAs with sufficient 
yield is crucial. Reproducible expression analysis of miRNAs is highly dependent on 
the quality of the RNA, which is often difficult to achieve in fibrotic tissue samples. 
Therefore, here we developed an optimized miRNA purification protocol for 
fibrous tissues that resulted in a significantly higher miRNA yield as compared to 
other methods in the literature. moreover, mirna obtained by our novel protocol 
gave more reproducible results in quantitative real-time Pcr (qrt-Pcr) analysis 
and more significant calls in DNA microarray analysis.
materials anD methoDs
Total RNA purification by using the TRIZOL method
Hearts were frozen and homogenized at the temperature of liquid nitrogen. To 50 mg 
of homogenized tissue (rat and mouse hearts) 1 ml TRIZOL reagent (Invitrogen) was 
added and incubated on room temperature for 5 minutes. After adding 200 μl dichlo-
rmethane, samples were vortexed for 15 seconds, and incubated at room temperature 
for 3 minutes. Samples were centrifuged at 12,000 × g for 15 minutes at 4 °C. 
Following centrifugation, the mixture separates into lower red, phenol-chloroform 
phase, an interphase, and a colorless upper aqueous phase. RNA remains exclusively 
in the aqueous phase. The upper aqueous phase was carefully transferred without 
disturbing the interphase into a fresh tube. to precipitate the rna from the aqueous 
phase 500 μl of isopropyl alcohol was added. After incubating the samples at 25 °C 
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for 10 minutes they were centrifuged at 12,000 × g for 10 minutes at 4 °C. The RNA 
pellet was washed with 750 μl 75% ethanol twice. 
RNA pellet was dried under vacuum for 5–10 minutes. RNA was dissolved in 
DEPC-treated water.
Modified Trizol method for fibrotic tissues
The same purification protocol was performed but because of the fibrotic nature of 
the heart samples, an additional Proteinase K digestion step was introduced. 
Homogenized heart tissue (50 mg) was solubilized with a proteinase K buffer con-
taining 120 μl Paraffin Tissue Lysis Buffer (Roche, Germany), 20 μl 10% SDS and 
50 μl Proteinase K (Roche, Germany). Samples were incubated at 55 °C for 30 min-
utes. after adding 1 ml triZol reagent to the lysate the above mentioned protocol 
was followed.
MiRNA purification by using the original protocol of the supplier
After disruption of heart samples in liquid nitrogen, the sample was dissolved in a 
20% Binding Buffer prepared from 80 μl of Binding Buffer and 320 μl of nuclease 
free water. All the other steps were done according to the Isolation of miRNA from 
Tissue protocol of the High Pure miRNA Isolation Kit (Roche, Cat. no. 05080576001). 
RNA was eluted from the second column by adding 100 μl Elution Buffer.
Improved miRNA isolation protocol for fibrotic tissues
our protocol is an improved version of the high Pure mirna isolation Kit (roche, 
Cat. no. 05080576001) with inserting several additional steps into the standard pro-
tocol. Mouse or rat hearts were frozen and homogenized at the temperature of liquid 
nitrogen. To 50 mg tissue powder 190 μl proteinase K solution was added (prepared 
as follows: 120 μl Paraffin Tissue Lysis Buffer (Roche, Germany), 20 μl 10% SDS 
and 50 μl of 20 mg/ml Proteinase K (Roche, Cat. No. 03115879001). Samples were 
incubated at 55 °C for 30 minutes. After incubation 325 μl Binding Buffer (Roche) 
and 320 μl Binding Enhancer (Roche) was added and loaded onto the filter columns 
(Rohce). Next the filters were washed in two steps with 500 and 300 μl of Washing 
Buffer (Roche) then the RNA was eluted by adding 40 μl Elution Buffer (Roche). 
After this step the microcentrifuge tube contains the eluted miRNA as well as the total 
RNA. Next 310 μl Binding Buffer was added to the eluate and the mixture was 
applied to a new filter tube. After a centrifuge step, the flow through was collected 
and 200 μl of Binding Enhancer was added. The mixture was loaded into the upper 
reservoir of a new column. Followed by the two washing steps with 500 and 300 μl 
of Washing Buffer, 40 μl 55 °C Elution Buffer was pipetted to the center of the col-
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umn membrane and incubated it for 2 minutes on room temperature before centrifu-
gation. The eluates were collected and the quality and quantity was assessed spectro-
photometrically (Nanodrop, USA) and with 2100 Bioanalyzer (Agilent). rna sam-
ples were prepared according to the manufacturer’s protocol and were loaded into the 
Eukaryote NanoChip (Agilent) and processed for 30 minutes. The RNA profile was 
automatically displayed as an individual electropherogram and as a gel-like image.
Reverse Transcription, QRT-PCR
The reverse transcription reaction was performed with the taqman® microrna 
reverse transcription Kit (applied Biosystems, united states, california). 350 ng of 
mirna (in the case of column-based kits) or 1000 ng (in the case of trizol-based 
purification) from each sample was reverse transcribed in the presence of 5X RT 
TaqMan® MicroRNA Assays (Applied Biosystems). 8 μl reaction mixture contained 
0.2 μl dNTPs, 1.50 μl MultiScribe™ Reverse Transcriptase (50 U/μL), 0.8 μl 10X RT 
Buffer, 0.9 μl MgCl2, 0.1 μl RNase Inhibitor (20 U/μL), 1.5 μl 5X RT primer and the 
template in a total volume of 3 μl. Reverse Transcription was carried out with the 
following cycling parameters in a thermocycler (Bioneer, Daedong, Korea): 16 °C for 
2 minutes, 42 °C for 1 minutes, 50 °C for 1 second, 45 cycles, then hold the samples 
on 85 °C for 5 minutes. After dilution with 64 μl of water, 9 μl of the diluted reaction 
mix was used as template in QRT-PCR. 
QRT-PCR was performed on a RotorGene 3000 instrument (Corbett Research, 
Sydney, Australia) with the TaqMan protocol [10]. A 20 μl reaction mixture contained 
10 μl TaqMan® Universal PCR Master Mix (Applied Biosystems), 1 μl of the 
TaqMan® MicroRNA Assays (Table 1) and 9 μl of the diluted cDNA. 
MiRNA analysis by using DNA-microarrays
A total of 50 ng purified miRNA was labeled using Agilent’s miRNA Complete 
Labeling and Hyb kit system (Agilent Technologies Palo Alto, CA, USA, p/n 5190-
0456). The protocol was briefly the following: 25–25 ng of two parallel samples were 
pooled together in a final volume of 2 µl and subjected to a dephosphorylation reac-
tion using Calf Intestinal Alkaline Phosphatase (CIP) at 37 °C for 30 minutes in the 
final volume of 4 µl. In the second step, 2.8 µl of DMSO was added to each sample 
for denaturation at 100 °C for 5 minutes and placed on ice immediately. Following 
this step, a ligation reaction was carried out using T4 RNA Ligase and Cyanine3-pCp 
in a total volume of 11.3 µl for 2 hours at 16 °C to label the RNA samples. The labeled 
samples were completely vacuum dried on medium-high (45 °C) heat setting and 
hybridized onto the surface of Agilent 8 × 15k Rat miRNA Microarray (Agilent 
Technologies, Palo Alto, CA, USA p/n G4473A). Dried and labeled samples were 
resuspended in 18 µl of nuclease-free water and denaturated at 100 °C for 5 minutes 
in the presence of 1× Blocking Agent and 1× Hi-RPM Hybridization Buffer in a final 
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volume of 45 µl and immediately placed on ice. These mixes were used for the 
hybridization, which was done as previously described [5, 10]. After hybridization 
the slides were washed in Gene Expression Wash buffer 1 containing Triton X-102 
from Agilent Technologies at room temperature for 1 minute than in Gene Expression 
Wash buffer 2 containing Triton X-102 at 37 °C for another 1 minutes before scan-
ning. Each array was scanned at 543 nm (for Cy3 labeling) in Agilent Scanner using 
the built-in XDR (Extended Dynamic Range) function with 5 um resolution. Output 
image analysis and feature extraction was done using Feature Extraction software of 
Agilent Technologies [4].
results anD Discussion
MiRNA preparation, determination of the quality and quantity of the 
purified nucleic acids
We optimized a miRNA purification protocol based on an existing kit which was 
originally developed for paraffin embedded tissue preparations, but was not appropri-
ate for fibrotic tissues. The schematic representation of the improved purification 
workflow based on reagents from the High Pure miRNA Isolation Kit (Roche) is 
presented in fig. 1.
We applied this improved approach to purify miRNAs from mouse and rat hearts. 
Using the same tissue as starting material we made total RNA purification with the 
traditional Trizol protocol, as well as Trizol protocol but inserting an extra step to 
proteolitically digest the muscle fibers with Proteinase K treatment. We also used 
silica-column based, commercially available miRNA purification kit from Roche as 
a control. After purification of miRNA or total RNA which contained miRNA the 
quantity of the purified nucleic acid was determined spectroscopically (Table 2). 
although the total rna yield for trizol and our improved protocol resulted in similar 
amount, in case of Trizol purification methods RNA contains all RNA types (total, 
Table 1
Purification efficiency (in μg) of different protocols
Standard deviation was determined from 4 independent runs  
and indicated in brackets after the average ct values
method rna yield
trizol 15.36 (4.30)*
trizol + ProtK 16.35 (3.57)*
roche 1.72 (0.76)
improved 10.97 (3.52)
*In case of Trizol purification RNA contains all RNA types 
(total, ribosomal and micro rna).
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Fig. 1. Schematic representation of novel cardiac miRNA purification workflow
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ribosomal and micro RNA). We found approximately six times more miRNA in the 
samples prepared by the improved protocol then in the samples obtained by standard 
purification kit from Roche.
The quality of the purified RNA was assessed by using BioAnalyzer chip (Agilent). 
The RNA profile of each sample was automatically displayed as an individual elec-
trophoretogram and as a gel-like image. By using trizol or trizol + Proteinase K 
method total RNA was obtained having ribosomal RNA, messenger RNA and 
approximately 2–5% miRNA. When we compared the electrophoretogram results of 
the two column-based miRNA protocol (the Roche protocol and the improved one), 
we found high quality miRNA in the preparations without ribosomal and messenger 
RNA. However there was substantial difference in the quantity of the purified miR-
NAs obtained by different protocols. Based on the Bioanalyzer results we found at 
least six times more miRNA in the samples prepared by the improved protocol then 
in the samples obtained by standard purification kit (Fig. 2). 
QRT-PCR of seven miRNAs on templates prepared with different 
protocols
We reverse transcribed RNA (total or miRNA enriched) obtained from mouse and rat 
hearts using four different protocols. in case of trizol and trizol + Proteinase K pro-
tocols instead of using 350 ng RNA we used 1000 ng as template. Although we used 
higher amount of RNA obtained from the Trizol method no miRNA amplification 
could be detected. This can be explained by the non-efficient homogenization of the 
heart tissue. By using column-based technologies all mirna (mir-1, mir-9, mir-
19a, miR-19b, miR-21, miR-23b, miR-24) could be successfully amplified. The 
TaqMan assays, used in this study to assess miRNA expression, are listed in Table 3. 
In each miRNA amplification experiments the improved protocol gave superior result 
over the samples obtained by the traditional or commercially available protocols. 
miRNA purification was also performed by using different kits from different ven-
Table 2
list of mirnas analyzed in this study
name assay iD mirBase accession
hsa-mir-1 002222 mimat0000416
hsa-mir-9 000583 mimat0000441
hsa-mir-19a 000395 mimat0000073
hsa-mir-19b 000396 mimat0000074
hsa-mir-21 000397 mimat0000418
hsa-mir-23b 000400 mimat0000418
hsa-mir-24 000402 mimat0000080
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dors, but none gave similar amplification efficiencies to our improved protocol (data 
not shown). In all miRNA genes tested other protocols in the QRT-PCR study result-
ed in higher ct and standard deviation values then that of the improved protocol. 
Standard deviation was calculated from individual Ct values obtained from three 
independent QRT-PCR reactions (Table 3). Amplification curves of miR-9, miR-21 
and mir-23b can be seen in figure 3.
To determine total RNA content of the samples, which could contaminate the puri-
fied miRNA samples, we run two QRT-PCR reactions which were specific to cDNAs 
of coding genes (HPRT, GAPDH). Amplification was successful in the case of Trizol-
based method and no amplification could be seen by using miRNA templates from 
the column-based methods (results are not shown). These results confirmed that the 
purified miRNA samples did not contain longer messenger RNAs.
Fig. 2. Analysis of purified micro RNA with traditional (upper panel) and our improved protocol (lower 
panel) on Bioanalyzer. Arrows show micro RNA populations
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Table 3
Amplification efficiency of purified miRNA from mouse heart by using QRT-PCR
average ct stDeV
mir-1 Protocol 1 12.86 0.57
Protocol 2 17.84 1.96
mir-9 Protocol 1 21.05 1.67
Protocol 2 26.77 3.17
mir-19a Protocol 1 18.98 0.56
Protocol 2 21.55 0.93
mir-19b Protocol 1 15.16 0.55
Protocol 2 18.25 2.34
mir-21 Protocol 1 16.12 0.47
Protocol 2 20.41 2.87
mir-23b Protocol 1 22.44 0.14
Protocol 2 27.09 5.03
mir-24 Protocol 1 12.63 0.58
Protocol 2 14.06 1.38
Fig. 4. images after hybridization of micro rnas prepared from traditional (left image) and our improved 
protocol (right image) on agilent rat micro rna microarrays
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DNA-microarray analysis of miRNAs on templates prepared with 
different protocols
To further test the quality of the purified miRNAs, fluorescent miRNA probes were 
prepared for DNA-microarray studies specific to miRNA profiling. The rat miRNA 
Agilent microarray contains probes for 350 miRNAs from the Sanger database v 
10.1. As we could detect only tiny amount of miRNAs from Trizol methods, which 
gave unreliable results during QRT-PCR, we used only those miRNA samples that 
were derived from the column-based protocols.
After hybridizing the probes onto Agilent rat-specific miRNA DNA-microarrays, 
images were generated by confocal laser scanning of the microarrays. Part of the 
scanned images can be seen in Figure 4. From the images we could conclude that 
hybridization of miRNA from the optimized protocol resulted in more spots with 
higher intensities. After data analysis of the scanned images the expression of 172 
mirnas could be detected in the case of the improved protocol and only 118 mir-
NAs with the traditional method.
Discussion
The number of studies showing the role of miRNAs in cardiac pathologies including 
cardiac hypertrophy, fibrosis, arrhythmias, and ischemia/reperfusion injury is increas-
ing rapidly. By using total RNA instead of purified miRNA to profile miRNA expres-
sion can limit sensitivity because of the relative abundance of small rnas in a total 
rna sample. therefore, traditional rna preparation protocols do not result in sensi-
tive detection of small RNA expression. There are several commercially available 
approaches to enrich low molecular weight RNA from biological samples however 
most of the protocols result in very low yield when fibrotic tissue is the sample. 
Besides having poor yield, the quality of miRNA is much worse in comparison to 
preparations from non-fibrotic tissues according to our experience. To overcome this 
challenge, we have improved a protocol which is based on the Roche purification 
method which was developed for paraffin-embedded tissues. 
The essence of our new method relies on efficient proteolytic digestion of fibrotic 
tissue, and a two-step purification protocol, which at first separate the total RNA 
including miRNAs, then on a new column miRNA is further purified by an addi-
tional elution. the schematic representation of the protocol can be seen in figure 1. 
The superior quality of the purified miRNAs obtained by our modified protocol was 
compared to that produced by trizol-based and commercially available kits.
We conclude, that our improved purification protocol, not only recovers high 
yields of mirnas, but the resulting mirna sample is more suitable for focused or 
global expression screening technologies, which can be achieved by QRT-PCR and/
or DNA-microarray experiments.
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